Physician profile

Albert W Steele

Internal Medicine · Madison, MS

NPI 1588771455

$3,309.99

in general payments reported to CMS, 2019-2025

30 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $466.60 2019-2022
Amgen INC. $395.07 2019-2022
Abbvie INC. $370.88 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $215.34 2019-2022
Pfizer INC. $186.34 2019-2021
Esperion Therapeutics, INC. $163.53 2021
Astrazeneca Pharmaceuticals Lp $154.78 2019-2021
Allergan, INC. $152.88 2019-2020
Merck Sharp & Dohme LLC $151.89 2019-2022
Takeda Pharmaceuticals U.S.A., INC. $144.64 2019-2022
Janssen Pharmaceuticals, INC $120.27 2019-2022
Glaxosmithkline, LLC. $119.29 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $79.36 2019-2022
Sanofi-Aventis U.S. LLC $74.06 2019-2020
Novartis Pharmaceuticals Corporation $57.17 2019-2022
Show all 30 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Albert W Steele

$3,309.99

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/298563/albert-w-steele

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.